FDA Review Of Merck’s Novel HIV Drug Isentress Shows No Clear Efficacy Or Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is asking its Antiviral Drugs Advisory Committee at the Sept. 5 meeting to consider HIV general treatment issues and postmarketing strategies for Merck’s integrase inhibitor, Isentress (raltegravir), which is up for accelerated approval.
You may also be interested in...
Isentress Gets Unanimous Nod From Advisory Committee, But May Get Limited Indication
Discussion of the indication for Merck’s raltegravir centered on whether the HIV therapy should be approved only for the highly treatment-experienced population studied in clinical trials.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.